Citigroup Cuts Bruker (NASDAQ:BRKR) Price Target to $53.00

Bruker (NASDAQ:BRKR) had its price objective decreased by Citigroup from $60.00 to $53.00 in a research note released on Wednesday morning, Marketbeat reports. Citigroup currently has a hold rating on the medical research company’s stock.

Several other equities analysts have also recently commented on the stock. Barclays increased their price target on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Finally, Leerink Partners raised their target price on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Bruker currently has an average rating of “Moderate Buy” and a consensus price target of $56.64.

Bruker Stock Performance

NASDAQ:BRKR opened at $53.41 on Wednesday. The stock has a market cap of $8.13 billion, a P/E ratio of -76.30, a PEG ratio of 1.57 and a beta of 1.28. Bruker has a 1-year low of $28.53 and a 1-year high of $65.30. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.72. The firm has a 50-day moving average of $58.50 and a two-hundred day moving average of $46.80.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts expect that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were issued a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s dividend payout ratio (DPR) is -28.57%.

Institutional Investors Weigh In On Bruker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new position in Bruker during the 4th quarter valued at $26,000. Global Retirement Partners LLC acquired a new stake in shares of Bruker in the second quarter valued at $38,000. Parallel Advisors LLC lifted its holdings in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares during the period. Allworth Financial LP boosted its stake in Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Finally, Essential Partners LLC bought a new position in Bruker during the first quarter valued at about $36,000. Institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.